The company reported strong Q3 revenue of $3.08 billion, showing double-digit growth. Positive clinical trial results for a kidney disease treatment, povetacicept, were announced, with plans for accelerated FDA approval submissions in 2025. The product portfolio is diversifying with global momentum for CASGEVY and broad uptake of other key products. Despite some recent volatility, the stock has delivered a 90.6% gain over five years. Analysts from Scotiabank and Evercore ISI maintain positive ratings with price targets, citing long-term growth potential and pipeline advancements.